ANDA 203422, held by Rising. Cinacalcet Hydrochloride.
As of Nov 16, 2026, ANDA 203422 (Cinacalcet Hydrochloride), held by Rising, was first approved by FDA on Oct 16, 2018, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2018 | Original application | Approved | None posted |
| Cinacalcet HydrochlorideEQ 30MG BASE · tablet;oral | Cinacalcet Hydrochloride | Discontinued |
| Cinacalcet HydrochlorideEQ 60MG BASE · tablet;oral | Cinacalcet Hydrochloride | Discontinued |
| Cinacalcet HydrochlorideEQ 90MG BASE · tablet;oral | Cinacalcet Hydrochloride | Discontinued |
| Jul 1, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 12, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 12, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 31, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 16, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters